Drugmaker, Retailers Strike Deal In Loestrin Antitrust MDL

Law360 (May 20, 2019, 6:08 PM EDT) -- Lupin Pharmaceuticals cut a deal that will allow it to escape antitrust claims leveled against it by Walgreens, CVS and other retailers that it conspired with two other pharmaceutical companies to keep generic versions of birth control drug Loestrin off the market.

The stipulation filed Friday in Rhode Island federal court releases Lupin from part of the multidistrict litigation that seven retailers leveled alongside two other sets of Loestrin buyers against Lupin, Warner Chilcott PLC and Watson Pharmaceuticals Inc. Lupin is still facing allegations from the other drug purchasers, namely corporate direct buyers such as drug wholesalers, and end-payors, which include health...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS